Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Bristol-Myers Squibb
N.N. Alexandrov National Cancer Centre
N.N. Alexandrov National Cancer Centre
Federation Francophone de Cancerologie Digestive
Tuen Mun Hospital
Jiangsu HengRui Medicine Co., Ltd.
AbbVie
Sun Yat-sen University
Seattle Project Corporation
Centre Hospitalier Universitaire de Besancon
Sun Yat-sen University
National Cancer Institute (NCI)
Qilu Pharmaceutical Co., Ltd.
University of California, San Francisco
Air Force Military Medical University, China
Federation Francophone de Cancerologie Digestive
Tocagen Inc.
Nanfang Hospital, Southern Medical University
Qingdao Central Hospital
AstraZeneca
Transgene
Medical Research Council
Intergroupe Francophone de Cancerologie Thoracique
GBG Forschungs GmbH
Sirtex Medical
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Australasian Gastro-Intestinal Trials Group